Cargando…

Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells

Purpose: Inflammation has been strongly associated with retinal damage in diseases such as diabetic retinopathy. Several studies have reported that high glucose exposure induces damage to the retinal vasculature. We and others have shown that high glucose can activate the NOD-like receptor family, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Youde, Steinle, Jena J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580119/
https://www.ncbi.nlm.nih.gov/pubmed/31354329
http://dx.doi.org/10.2147/JIR.S210441
_version_ 1783427974024921088
author Jiang, Youde
Steinle, Jena J
author_facet Jiang, Youde
Steinle, Jena J
author_sort Jiang, Youde
collection PubMed
description Purpose: Inflammation has been strongly associated with retinal damage in diseases such as diabetic retinopathy. Several studies have reported that high glucose exposure induces damage to the retinal vasculature. We and others have shown that high glucose can activate the NOD-like receptor family, pyrin domain containing family member 3 (NLRP3) pathway, leading to increased levels of cleaved caspase 1 and IL-1β to activate a number of inflammatory pathways in the retina. Methods: We used retinal endothelial cells grown in normal (5 mM) or high (25 mM) glucose or retinal lysates from endothelial cell-specific knockout mice for exchange protein activated by cAMP 1 (Epac1). Human recombinant protein kinase R (PKR) or C16, a PKR inhibitor, was used on the cells to dissect PKR and NLRP3 signaling. Results: Using retinal endothelial cells (REC) in high glucose and whole retinal lysates from endothelial cell-specific knockout of Epac1, we demonstrate that Epac1 regulates PKR phosphorylation. Using an Epac1 agonist or PKR inhibition with C16, we demonstrated that loss of PKR resulted in reduced NLRP3, cleaved caspase 1, and IL-1β levels. Furthermore, despite the addition of recombinant human PKR, Epac1 was still able to significantly reduce NLRP3 signaling. Conclusion: Overall, these studies demonstrated that PKR regulates the NLRP3 inflammasome in REC, and that Epac1 inhibition of PKR can reduce activation of the NLRP3 inflammasome.
format Online
Article
Text
id pubmed-6580119
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65801192019-07-26 Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells Jiang, Youde Steinle, Jena J J Inflamm Res Original Research Purpose: Inflammation has been strongly associated with retinal damage in diseases such as diabetic retinopathy. Several studies have reported that high glucose exposure induces damage to the retinal vasculature. We and others have shown that high glucose can activate the NOD-like receptor family, pyrin domain containing family member 3 (NLRP3) pathway, leading to increased levels of cleaved caspase 1 and IL-1β to activate a number of inflammatory pathways in the retina. Methods: We used retinal endothelial cells grown in normal (5 mM) or high (25 mM) glucose or retinal lysates from endothelial cell-specific knockout mice for exchange protein activated by cAMP 1 (Epac1). Human recombinant protein kinase R (PKR) or C16, a PKR inhibitor, was used on the cells to dissect PKR and NLRP3 signaling. Results: Using retinal endothelial cells (REC) in high glucose and whole retinal lysates from endothelial cell-specific knockout of Epac1, we demonstrate that Epac1 regulates PKR phosphorylation. Using an Epac1 agonist or PKR inhibition with C16, we demonstrated that loss of PKR resulted in reduced NLRP3, cleaved caspase 1, and IL-1β levels. Furthermore, despite the addition of recombinant human PKR, Epac1 was still able to significantly reduce NLRP3 signaling. Conclusion: Overall, these studies demonstrated that PKR regulates the NLRP3 inflammasome in REC, and that Epac1 inhibition of PKR can reduce activation of the NLRP3 inflammasome. Dove 2019-06-12 /pmc/articles/PMC6580119/ /pubmed/31354329 http://dx.doi.org/10.2147/JIR.S210441 Text en © 2019 Jiang and Steinle. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jiang, Youde
Steinle, Jena J
Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title_full Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title_fullStr Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title_full_unstemmed Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title_short Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells
title_sort epac1 inhibits pkr to reduce nlrp3 inflammasome proteins in retinal endothelial cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580119/
https://www.ncbi.nlm.nih.gov/pubmed/31354329
http://dx.doi.org/10.2147/JIR.S210441
work_keys_str_mv AT jiangyoude epac1inhibitspkrtoreducenlrp3inflammasomeproteinsinretinalendothelialcells
AT steinlejenaj epac1inhibitspkrtoreducenlrp3inflammasomeproteinsinretinalendothelialcells